Cash

£219K

+42.1% vs 2023

Net assets

£1M

-34.4% vs 2023

Employees

51

-1.9% vs 2023

Profit before tax

-£564K

+29.8% vs 2023

Profile

Company number
07503850
Status
Active
Incorporation
2011-01-24
Last accounts made up
2024-12-31
Account category
FULL
Primary SIC
21100
Hubs
UK Healthcare

Net assets

6-year trend · vs UK Healthcare median

£0£2.5m£5m201920202021202220232024
RANSOM NATURALS LIMITED

Accounts

6-year trend · latest 2024-12-31

Metric Trend 2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Turnover
Operating profit
Profit before tax -£803,404-£564,007
Net profit -£875,449-£679,895
Cash £48,972£69,401£153,909£218,734
Total assets less current liabilities £3,440,656£3,190,688£2,268,795£1,980,742
Net assets £2,868,987£2,854,240£1,978,791£1,298,896
Equity £2,756,352£2,745,710£2,868,987£2,854,240£1,978,791£1,298,896
Average employees 44505251
Wages £2,439,160£2,523,601

Values shown as filed in iXBRL accounts. indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers

Audit & accounting basis

From AI-extracted PDF accounts

Accounting basis
FRS 102
Reporting scope
Standalone (parent only)
Abridged
Yes — abridged accounts (limited disclosure)
Auditor
DSG Audit
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Significant events

Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers

People

3 active · 10 resigned

Name Role Appointed Born Nationality
DIDLICK, Philip James Director 2012-04-30 Jun 1976 British
O'BRIEN, Gerald Francis Director 2012-01-06 Jan 1949 British
O'BRIEN, Padraic Marc Director 2012-01-06 Jun 1979 British
Show 10 resigned officers
Name Role Appointed Resigned
BROMILEY, Mark Secretary 2021-07-02 2025-03-07
DIDLICK, Philip Secretary 2012-04-30 2021-07-02
WHITCOMB, Frederick Francis Secretary 2011-02-23 2012-01-06
OLSWANG COSEC LIMITED Corporate Secretary 2011-01-24 2011-02-23
BROMILEY, Mark Director 2021-07-02 2025-03-07
JONES, Roger Spencer, Sir Director 2011-02-23 2012-01-06
MACKIE, Christopher Alan Director 2011-01-24 2011-02-23
WHITCOMB, Frederick Francis Director 2011-02-23 2012-01-06
OLSWANG DIRECTORS 1 LIMITED Corporate Director 2011-01-24 2011-02-23
OLSWANG DIRECTORS 2 LIMITED Corporate Director 2011-01-24 2011-02-23

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Obg Pharmaceuticals Ltd Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2024-01-12 Active
Mr Gerald Francis O'Brien Individual Significant influence 2016-04-06 Ceased 2024-01-12
Mrs Brigid Christina Obrien Individual Significant influence 2016-04-06 Ceased 2024-01-12

Filing timeline

Last 20 of 85 total filings

Date Type Category Description
2026-02-17 MR04 mortgage mortgage satisfy charge full
2025-12-21 CS01 confirmation-statement confirmation statement with no updates
2025-09-10 AA accounts accounts with accounts type full
2025-03-11 TM01 officers termination director company with name termination date
2025-03-11 TM02 officers termination secretary company with name termination date
2025-01-10 CS01 confirmation-statement confirmation statement with no updates
2024-09-30 AA accounts accounts with accounts type small
2024-05-15 MR01 mortgage mortgage create with deed with charge number charge creation date
2024-02-13 PSC07 persons-with-significant-control cessation of a person with significant control
2024-02-13 PSC07 persons-with-significant-control cessation of a person with significant control
2024-02-13 PSC02 persons-with-significant-control notification of a person with significant control
2024-02-13 MR01 mortgage mortgage create with deed with charge number charge creation date
2024-01-16 CS01 confirmation-statement confirmation statement with no updates
2023-09-29 AA accounts accounts with accounts type small
2023-01-17 CS01 confirmation-statement confirmation statement with no updates
2022-09-30 AA accounts accounts with accounts type small
2022-01-10 CS01 confirmation-statement confirmation statement with no updates
2021-07-02 AP03 officers appoint person secretary company with name date
2021-07-02 AP01 officers appoint person director company with name date
2021-07-02 TM02 officers termination secretary company with name termination date

Credit score

Altman Z″ (private-firm) · reference 2024-12-31

-1.79

DISTRESS

Altman Z″

  • Working capital / Total assets -0.244 × 6.56 = -1.60
  • Retained earnings / Total assets 0.000 × 3.26 = +0.00
  • EBIT / Total assets -0.062 × 6.72 = -0.42
  • Book equity / Total liabilities 0.220 × 1.05 = +0.23

Bands: > 2.6 safe · 1.1–2.6 grey · < 1.1 distress. Z″ is a public-formula baseline, not a substitute for adverse-data signals (CCJs, charges, gazette notices) — those land in a later pass.

Activity Score

Filings velocity, capital events, officer churn, accounts trajectory

Activity Score not yet computed for this company.

Official Companies House page